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Abstract
Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the 
heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to 
prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical 
disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there 
is a need for robust biomarkers of beta cell health, which could provide insight into 
pathophysiological differences in disease course, improve disease prediction, increase the 
understanding of therapeutic responses to immunomodulatory interventions and identify 
individuals most likely to benefit from these therapies. In this review, we outline current literature, 
limitations and future directions for promising circulating markers of beta cell stress and death in 
type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs 
and circulating DNAs.
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Introduction
In recent years, it has become increasingly apparent that the definition of type 1 diabetes as a 
purely autoimmune disease belies its strikingly heterogeneous pathophysiology. For 
example, postmortem studies show that in individuals with type 1 diabetes only about 24% 
of those aged <14 years exhibit evidence of islet inflammation (insulitis) and even fewer 
(only 10%) aged >15 years have detectable insulitis [1]. Likewise, loss of islet insulin 
positivity (once thought to be the uniform hallmark of type 1 diabetes) displays striking 
variability, with some individuals exhibiting insulin positivity in up to 50% of islets at type 1 
diabetes clinical diagnosis [2]. This heterogeneous pathology is reflected in clinical trials of 
immune-modulating drugs, which have shown limited success in slowing destruction/
dysfunction of beta cells in type 1 diabetes [3]. Taken together, these studies suggest that the 
institution of therapies that diminish both immune responses against beta cells and boost 
beta cell resistance to stress might be needed to prevent or reverse type 1 diabetes. Trials of 
such therapies, or their implementation at preclinical stages of disease, require high-
confidence indices of beta cell health and disease. Currently, indices such as the Diabetes 
Prevention Trial-Type 1 Risk Score (DPTRS), Index60, islet-derived autoantibody number 
and titres, first-phase insulin response to an intravenous glucose load and alterations in 
HbA11c are used to stratify risk of progression to overt type 1 diabetes [4, 5]. While these 
indices reflect prevailing autoimmunity, beta cell function or glycaemic control, none 
directly reflect the health or survival of beta cells. In this review, we summarise the status of 
research into biomarkers of beta cell stress and death in type 1 diabetes.
Beta cell stress and death: origins of biomarkers
The beta cell, like most cell types, has highly conserved molecular responses to cope with 
stressful signals (e.g. viral infections, proinflammatory cytokines, metabolic overload). 
These molecular responses have the common goal of stress ‘remediation’, whereby an 
attempt is made to mitigate the impact of the stressor on beta cell health. Failing stress 
mitigation, cell death pathways eventually prevail. In recent years, it has become apparent 
that the unfolded protein response (UPR) pathway is a focal point of extracellular stress 
signalling in type 1 diabetes and exemplifies remediation vs cell death balance. The UPR in 
beta cells is activated under conditions of inflammation, oxidative stress and insulin 
production/folding imbalance [6]. and results in rapid translational inhibition to alleviate the 
deleterious effects of accumulating misfolded proteins in the endoplasmic reticulum (ER). In 
the setting of persistent and severe stress, the UPR activates c-Jun N-terminal kinase (INK) 
and C/EBP-homologous protein (CHOP) cascades, leading to apoptosis. The UPR also 
exemplifies how intracellular biomolecules, such as proteins and nucleic acids, might escape 
extracellularly [7]. thereby providing circulating biomarkers that reflect the cellular state of 
emergency.
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Three categories of potential conduits for cellular escape of biomolecules are shown in Fig. 
1: (1) The ER–Golgi secretory network; (2) extracellular vesicle (EV) pathways and (3) 
apoptotic bodies/cellular necrosis. Specifically, the ER–Golgi network is the physiological 
pathway through which the processing, folding and secretion of proteins (e.g. insulin, 
amylin) is routinely achieved in beta cells. Stress-induced activation of the UPR has a 
profound impact on the amount and structure of the proteins released through this network. 
The EV pathways, by contrast, are conduits through which a multitude of biomolecules, 
including nucleic acids, proteins, lipids and metabolites, are released under physiological 
and pathological conditions [8]. In this pathway, biomolecules enter EVs (e.g. exosomes, 
microvesicles; ranging in size from 50 to 1000 nm) either through endosomes or plasma 
membrane outcroppings (for a review, see [8]). The content of EVs changes dynamically 
according to the physiological state of the cell. Importantly, EVs may carry and present 
antigens to the immune system or communicate apoptotic signals between beta cells [9, 10]. 
Last, release of biomolecules within cellular fragments (apoptotic bodies) or directly into 
circulation (through spillage of cellular contents) is observed following apoptosis or 
necrosis, respectively [11]; biomarkers released in such fashion represent an end-stage fate 
of beta cells.
Biomarkers of beta cell stress and death
Circulating proteins
Because beta cell plasma membranes are disrupted upon cell necrosis, quantification of 
changes in circulating beta cell proteins released via this mechanism could serve as a marker 
of beta cell death. Along these lines, plasma glutamate decarboxylase 65 kDa (GAD65), 
which is specific to islets and neural and reproductive tissues, was acutely increased in a 
small group of humans receiving islet transplants [12]. Analysis of GAD65 in at-risk or 
recently diagnosed individuals is needed to understand the potential of this marker in the 
context of type 1 diabetes.
Multiple studies have explored the possibility of using abnormalities in prohormone 
processing as markers of beta cell stress. The hallmark of a normally functioning beta cell is 
production and release of insulin in response to nutrients, and abnormalities in insulin 
production and processing are among the earliest markers of beta cell dysfunction. Under 
conditions of beta cell stress (e.g. autoimmune or inflammatory stress), hormone processing 
capabilities become overwhelmed and incompletely-processed intracellular proinsulin is 
released extracellularly either through the ER–Golgi pathway or in EVs [10, 13]. Circulating 
proinsulin molecules can be compared with circulating mature insulin or C-peptide, with 
increases in relative circulating proinsulin reflecting beta cell dysfunction [7]. ProinsulimC-
peptide (PI:C) ratios outperform proinsulin:insulin ratios in predicting incident diabetes in 
populations with insulin resistance, as circulating insulin values can reflect altered hepatic 
insulin clearance [14].
Analyses of relatives at risk for type 1 diabetes indicate that elevated PI:C ratios are 
predictive of progression to diabetes and can augment the performance of other traditional 
markers of diabetes risk, such as autoantibodies [15–17]. A comparison of fasting PI:C ratio 
vs first-phase insulin secretion (measured using hyperglycaemic clamp studies) in 
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autoantibody-positive relatives suggested that fasting PI:C ratio, adjusted for differences in 
insulin sensitivity, is as informative of impending type 1 diabetes as the more invasive clamp 
studies [16]. Further analyses of at-risk groups suggest that this marker performs best in pre-
adolescent individuals, in whom differences in ratios between those who progressed and 
those who did not progress to type 1 diabetes were the most pronounced [17]. Several 
groups have reported that PI:C ratios may also be increased in euglycaemic relatives of 
individuals with type 1 diabetes, even those who are autoantibody-negative or do not have 
high-risk HLA genotypes [18–20].
At the time of diagnosis of type 1 diabetes, circulating PI:C ratios have been found to be 
elevated relative to those in control groups without diabetes [21, 22]. However, there is no 
clear consensus on PI:C ratios at the time of clinical remission/the ‘honeymoon’ period. 
Studies in older individuals suggest a reduction in PI:C ratios during the honeymoon period 
of type 1 diabetes compared with levels at diagnosis, whereas a report in paediatric 
participants suggested continued elevations in PI:C ratios during this period, suggestive of 
persistent beta cell stress despite improved C-peptide production [21–23].
Of note, PI:C ratios may allow identification of individuals most likely to benefit from 
immunomodulatory therapies, as elevations in ratios at type 1 diabetes diagnosis were 
associated with subsequent response to ciclosporin treatment [21]. A recent analysis of 
donor pancreases from individuals with longstanding type 1 diabetes suggested that the 
majority of individuals retain islet proinsulin immunostaining, despite very low or absent 
islet C-peptide immunostaining [24]. Other reports have identified circulating proinsulin in 
C-peptide-negative individuals with longstanding type 1 diabetes, raising the possibility that 
circulating proinsulin may be more useful as a biomarker of persistent or remaining beta 
cells as compared with insulin or C-peptide [25, 26]. Larger-scale longitudinal studies with 
sensitive C-peptide assays and stimulated analyses of beta cell function are required to fully 
elucidate this possibility.
The altered processing of other prohormones in association with beta cell dysfunction may 
also represent other promising novel stress-related biomarkers. A recent report identified 
elevations in plasma pro-islet amyloid polypeptide (pro-IAPP) relative to total IAPP in a 
cross-section of children with longstanding type 1 diabetes and islet transplant recipients 
with type 1 diabetes [27]. Unexpectedly, pro-IAPP levels were not elevated in samples from 
two cross-sections of individuals with type 2 diabetes, despite elevations in circulating 
proinsulin [27]. Additional longitudinal studies are needed to better understand the efficacy 
of circulating pro-IAPP as a marker of beta cell stress in at-risk populations.
One drawback of measuring prohormone ratios is that there may be overlap between some 
individuals with type 1 diabetes and control individuals without diabetes, emphasising the 
heterogeneity in beta cell prohormone processing dysfunction among groups with or at risk 
for type 1 diabetes. Additionally, the following questions regarding the pathophysiology 
surrounding these markers in type 1 diabetes remain to be answered: (1) what are the 
underlying mechanisms of prohormone processing dysfunction in type 1 diabetes (i.e. ER 
stress vs alterations in expression of processing enzymes and/or genetic predisposition to 
altered prohormone processing)?; (2) will differences in prohormone ratios predict 
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heterogeneity in clinical disease course or responses to different immunomodulatory 
therapies?; (3) which will perform more effectively as biomarkers of beta cell stress in type 
1 diabetes: intact or total (inclusive of all partially processed split products) prohormones?
Circulating RNAs
A variety of RNA types have been measured in the circulation as cell-free species that have 
the potential to indicate beta cell health. To date, the greatest emphasis has been on non-
coding RNAs, which include microRNAs (miRNAs), long non-coding RNAs, small 
nucleolar RNAs and circular RNAs. These function post-transcriptionally to alter cellular 
identity and function. Circulating miRNAs have generated perhaps the most significant 
interest as biomarkers of disease. Although these small RNAs (21–23 nucleotides) largely 
function intracellularly, emerging data suggest that they can be shed extracellularly from 
apoptotic or necrotic cells, in association with lipoprotein particles or Argonaute-2 protein 
complexes, or as molecular cargo within EVs (reviewed in [28]), possibly as a means of 
intercellular communication. Notably, although groups have studied miRNAs in the 
circulation or in isolated human islets [29]. none have yet described beta cell miRNAs in the 
context of human pancreatic tissue in situ. Because miRNAs are important regulators of 
gene expression within the cell, circulating miRNAs can provide a ‘liquid biopsy’ of 
changes in gene expression in response to different diseases, including those occurring in the 
beta cell in diabetes [8]. In this context, miR-375-5p (hereafter referred to as miR-375) has 
been studied most extensively as a putative biomarker of beta cell death [30]. Relative 
expression of miR-375 is enriched in mouse islets compared with other tissues and miR-375 
is released extracellularly as mouse islets die [30]. In studies of mice under non-stressed 
conditions, beta cells only contribute ~1% of the total miR-375 signal in plasma [31]. 
However, acute beta cell death caused by streptozotocin is associated with increases in 
plasma miR-375 and plasma levels are also increased in NOD mice models of diabetes prior 
to diabetes onset [30, 31]. Nevertheless, data in human type 1 diabetes are inconclusive, with 
some reports showing increased circulating levels of miR-375 in those with type 1 diabetes 
and others showing unchanged or decreased levels compared with control individuals 
without diabetes [30–35].
Unbiased approaches have been used in an attempt to identify other miRNAs that may be 
associated with individuals with or at risk for diabetes. Datasets arising from such 
approaches in type 1 diabetes-related populations have been reported, but these data have so 
far failed to identify consistently differentially expressed miRNAs in such cohorts [32, 35–
39]. These outcomes are likely related to miRNA release from multiple organs, leading to 
relatively nonspecific signatures in the circulation. An alternative approach to analysis of 
global circulating miRNAs is characterisation of EV-associated miRNAs. The miRNA cargo 
within EVs is dynamically modulated under different physiological conditions and disease 
states [8] and, as such, treatment of beta cells in vitro with inflammatory cytokines induces 
the differential expression of miRNAs within EVs compared with control cells [9]. 
Differences in circulating EV miRNA cargo are present when comparing people with type 1 
diabetes with control individuals without diabetes [33, 40]. Importantly, these EV-associated 
miRNAs can be distinct from total serum or plasma miRNA levels and may represent 
different modes through which miRNAs are released or the nature of the EVs in which they 
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are released (e.g. exosomes vs microvesicles vs apoptotic bodies) [33]. For example, while 
miR-375 was found to be increased in both serum EVs and total serum from a cross-section 
of children with new-onset type 1 diabetes, serum EV and total serum miR-21-5p levels 
were discordant in individuals with diabetes (increased in serum EVs and decreased in total 
serum samples) [33]. Although work in circulating EV-associated miRNAs is limited by 
specificity issues (similar to those encountered in global circulating miRNA analyses), the 
use of EVs has the potential for future analyses enriching for beta cell or islet-derived EVs 
[41].
Another area that requires further development is the identification of other types of RNAs 
that are released by beta cells under diabetogenic stress conditions. These could include 
mRNAs, mRNA spliced variants and other non-coding RNAs that play important roles in the 
regulation of islet function and may be altered in the circulation in type 1 diabetes. 
Identification of other classes of cell-free RNAs emanating predominantly from beta cells 
should allow for identification of more specific beta cell-stress signatures in type 1 diabetes. 
To date, reports are lacking on extracellular RNAs that are truly beta cell-specific or are 
specifically released in response to beta cell death.
Circulating DNA
The appearance of cell-free DNA in the circulation is thought to arise primarily from 
apoptotic or necrotic cells, since DNA does not undergo routine turnover in living, quiescent 
cells. Although the DNA sequence of every non-tumorous cell in an organism is identical, 
the epigenetic modification of DNA (e.g. cytosine methylation) can vary from cell type to 
cell type. In this respect, modifications of DNA that are unique to beta cells could allow for 
the attribution of circulating DNA fragments bearing that modification to dying beta cells. 
To date, all studies involving circulating DNA biomarkers of beta cell death have relied on 
the notion that specific genes that are repressed bear cytosine methylation marks, whereas 
genes that are expressed are devoid of this modification. As such, the beta cell-specific gene 
encoding preproinsulin (INS) has been the major focus of investigations into biomarkers of 
beta cell death, and studies have shown the absence of cytosine methylation at this gene to 
be a characteristic feature of beta cells [42].
Discrimination of methylated vs unmethylated INS is achieved by the bisulphite reaction, 
which converts unmethylated cytosines to uracil (equivalent to thymidine) and can be 
differentially detected by PCR. Using different PCR methodologies that targeted different 
cytosine residues in the INS gene, several studies have demonstrated elevated levels of 
unmethylated INS DNA in the circulation of mice acutely treated with streptozotocin or in 
NOD mice just prior to diabetes development. These findings are consistent with the notion 
that dying beta cells give rise to increasing levels of circulating unmethylated INS DNA [43, 
44]. These findings were subsequently verified in individuals before progression to or with 
new- or recent-onset type 1 diabetes [45–47]. subpopulations of individuals with ketosis-
prone diabetes [48] and in individuals post-islet transplant [49–51]. all of whom are credibly 
in states where beta cells are dying. Other beta cell-enriched genes have also been 
investigated (GCK, IAPP) [52, 53] but the use of these genes for stratifying populations with 
or at risk for type 1 diabetes remains untested.
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Whereas the sensitivity of these DNA-based biomarkers seems to be of little concern (since 
they are detectable using sensitive PCR techniques), a major limitation of the availability of 
DNA-based biomarkers is their specificity. Bisulphite-based sequencing of different human 
tissues [51] showed that some tissues exhibit evidence of unmethylated INS DNA, albeit at 
low levels relative to the levels of methylated INS (<20%). Nevertheless, given the 
difference in mass between beta cells (very low) and other cell types in the body, it is 
conceivable that an unmethylated INS signal could arise from one of these other tissues. A 
recent study showed that many beta cell-specific gene promoters also demonstrate 
comparable rates of methylation/unmethylation in alpha cells [54]. This finding reflects the 
common origin of all islet cell types but emphasises that the DNA biomarkers identified to 
date probably at best reflect islet cell death and not beta cell death. To address the specificity 
concern, two approaches are necessary: (1) determination of unmethylated DNA levels by 
different laboratories, using samples from individuals with type 1 diabetes that have been 
provided blindly by a central laboratory (as done in the original validation of autoantibodies; 
these tests are presently ongoing); and (2) genome-wide approaches to screen cytosines that 
exhibit differential methylation in human beta cells to obtain unbiased identification of 
genes (irrespective of their expression pattern) that might exhibit better beta cell-type 
specificity.
Conclusions and perspectives
The clinical heterogeneity of type 1 diabetes limits the accuracy of current risk prediction 
tools, as well as the effectiveness of current prevention and treatment strategies. These 
limitations have led to mounting recognition of a need for improved tools to monitor 
evolving beta cell stress and death and their contributions to diabetes development. To date, 
significant advances have been made, but these have been limited by sensitivity, specificity 
and reproducibility of individual markers. Further identification and validation of highly 
specific beta cell markers will facilitate their implementation in diabetes prediction and 
clinical use. These limitations may also arise in part because of the cross-sectional nature of 
many biomarker analyses, whereas beta cell stress and death in evolving type 1 diabetes are 
most likely waxing and waning processes. Longitudinal analyses (based on blinded samples) 
using promising beta cell biomarkers in at-risk populations are necessary to understand 
better the accumulating changes in beta cell health as disease develops over time. 
Additionally, results to date suggest that, as with the heterogeneity in the course of clinical 
diabetes, biomarkers of beta cell stress and death are variably altered in at-risk individuals. 
Thus, long-term success will likely require the use of a combination of multiple beta cell and 
other non-beta cell biomarkers to provide a comprehensive panel of markers of beta cell 
health in the context of evolving autoimmunity. Such a panel would allow for a more 
personalised approach to diabetes prevention and care, permitting identification of 
individuals at highest risk for diabetes development and a better understanding of individual 
responses to therapies.
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IAPP Islet amyloid polypeptide
PI:C Proinsulin-to-C-peptide
UPR Unfolded protein response
miRNA MicroRNA
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Moving forward in the field
Improved tools to monitor beta cell stress and death are required to improve type 1 
diabetes prediction, prevention and treatment. The following steps are required to 
improve the current landscape of biomarkers of beta cell health in type 1 diabetes:
1. Identification and validation of more specific beta cell biomarkers
2. More rigorous analyses of prospective biomarkers using samples from 
longitudinal studies
3. Generation of a comprehensive multiple-biomarker panel that reflects the 
state of beta cell health at different stages throughout the disease course
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Potential conduits for cellular escape of biomolecules: (1) the ER–Golgi secretory network 
is the physiological pathway through which the processing, folding and secretion of proteins 
(e.g. insulin, amylin) is routinely achieved in beta cells; (2) the EV pathways are recognised 
as conduits through which a multitude of biomolecules, including nucleic acids, proteins, 
lipids and metabolites are released, either through endosomes (exosomes) or plasma 
membrane outcroppings into EVs (microvesicles); (3) apoptosis/cellular necrosis results in 
the release of biomolecules within cellular fragments (apoptotic bodies) or directly into 
circulation (through necrosis and spillage of cellular contents) and represents an end-stage 
fate of beta cells. MVB, multivesicular body. This figure is available as a downloadable slide
Sims et al. Page 14
Diabetologia. Author manuscript; available in PMC 2019 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
